Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation (ML20981)

This study has been completed.
Sponsor:
Collaborators:
Sun Yat-sen University
Shanghai Chest Hospital
RenJi Hospital
Guangdong Provincial People's Hospital
Peking Union Medical College Hospital
Information provided by (Responsible Party):
Caicun Zhou, Tongji University
ClinicalTrials.gov Identifier:
NCT00874419
First received: April 1, 2009
Last updated: September 23, 2014
Last verified: September 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2012
  Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
No publications provided by Tongji University

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):